Details checkedClinical trial listing onlyCheckedregistry

NIDCD atorvastatin cisplatin otoprotection study

Also known as: Atorvastatin, 21-DC-0002, 210002, NCT04915183

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Active

Target Gene

—

Route / Mode

Oral tablet

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, cisplatin-ototoxicity, head-and-neck-cancer, otoprotection

Trial IDs

Mechanism

Oral atorvastatin 40 mg daily during and after cisplatin-based chemoradiation, evaluated for reduction of cisplatin-induced hearing loss in adults with head and neck squamous cell carcinoma.

Indications

Hearing Loss Cisplatin-Induced Hearing Loss Ototoxicity

Notes

Verified as an NIH/NIDCD-sponsored Phase 2 study, not an industry program. The registry lists the trial as recruiting and evaluates atorvastatin for cisplatin-induced hearing loss prevention in head-and-neck cancer treatment.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT04915183, 21-DC-0002, 210002

Open

Key Events

2021-06-07

NIDCD atorvastatin cisplatin hearing-loss prevention study first posted

2026-06-05

ClinicalTrials.gov update lists the atorvastatin study as recruiting

Clinical Trials (1)